Wavelength Pharmaceuticals has significantly expanded production of APIs for certain pharmaceuticals being used to manage respiratory critical care patients as a result of the coronavirus pandemic. Products in demand include Midazolam, Cisatracurium, and Rocuronium. Wavelength also recently launched new API CDMO (contract development and manufacturing) services that leverage the company’s expertise in complex chemistry, crystalline forms, and particle design for development and manufacturing ...